Free Trial
NASDAQ:BTTX

Better Therapeutics 5/14/2026 Earnings Report

Better Therapeutics logo
$0.0001 0.00 (0.00%)
As of 09:30 AM Eastern

Better Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.22
Beat/Miss
N/A
One Year Ago EPS
N/A

Better Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.04 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Better Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Better Therapeutics Earnings Headlines

BTTX Better Therapeutics, Inc. - Seeking Alpha
Janux Therapeutics Inc (JANX) Receives a Buy from BTIG
Elon Musk’s $1 Quadrillion AI IPO
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.tc pixel
See More Better Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Better Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Better Therapeutics and other key companies, straight to your email.

About Better Therapeutics

Better Therapeutics (NASDAQ:BTTX) is a clinical-stage digital therapeutics company focused on developing prescription software-based treatments for cardiometabolic diseases. Its lead product candidate, BT-001, is a behavior-change program delivered via a smartphone application, designed to address underlying drivers of type 2 diabetes and hypertension through cognitive behavioral therapy techniques. The company’s platform is built to engage patients in personalized lifestyle modification, leveraging real-time feedback and data analytics to support sustained clinical improvements.

BT-001 is being evaluated in pivotal clinical trials under FDA investigational device exemptions, with studies examining its impact on glycemic control and blood pressure reduction. Better Therapeutics collaborates with academic research centers and healthcare providers to validate its therapeutic approach, aiming to secure FDA clearance as a prescription digital therapeutic. The company’s evidence-generation strategy includes randomized controlled trials and real-world evidence initiatives to demonstrate safety, efficacy and long-term adherence benefits.

Founded in 2016 and headquartered in Redwood City, California, Better Therapeutics operates primarily in the United States, with plans to expand its commercial and regulatory footprint internationally. The company is led by CEO Sean Duffy, who brings extensive experience in digital health innovation, and a management team comprised of professionals in clinical development, regulatory affairs and commercial strategy. Better Therapeutics has assembled a scientific advisory board featuring thought leaders in endocrinology, behavioral science and digital health.

Better Therapeutics aims to transform chronic disease management by providing scalable, evidence-based digital interventions that complement traditional medical therapies. Its mission is to empower patients and healthcare systems with tools that address root causes of cardiometabolic conditions, improve clinical outcomes and reduce long-term healthcare costs.

View Better Therapeutics Profile